Cardea Bio, Inc., U.S-based manufacturer of a biology-enabled transistor technology made from graphene-based biosensors, recently raised $6.5 Million in a series A extension that brings its A round total above $20M.

The new capital infusion is led by the life sciences and biotechnology focused investor 3E Bioventures Capital and joined by existing investors. Proceeds from the financing will be used to further develop Cardea’s proprietary Transistor platform, in order to significantly expand mass-manufacturing and further grow Cardea’s number of commercial partnerships.

Additional recent raises for Cardea included its September 2020 raise of $7.5 Million in series A2 financing, and the March 2019 raise of $7.8 Million in Series A-1 financing.

Source: 
Tags: